| 23.91 9.75 (64.36%) | 03-19 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
OpGen, Inc. is a precision medicine company dedicated to developing and commercializing advanced molecular microbiology solutions for both U.S. and international markets. Its comprehensive product suite includes the Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test designed to pinpoint various bacterial nucleic acids and genetic markers of antimicrobial resistance (AMR) from bacterial colonies sourced from diverse specimen types. The company also offers Curetis CE-IVD-marked polymerase chain reaction (PCR)-based test kits for SARS-CoV-2 detection. Beyond diagnostics, OpGen provides sophisticated platforms like the ARES Technology Platform. This platform features the ARES reference database, which leverages next-generation sequencing technology and artificial intelligence-powered bioinformatics to predict antibiotic response for antimicrobial resistance. Another core offering is the Unyvero Platform, an automated, sample-to-answer molecular diagnostics system. It seamlessly integrates automated sample preparation, analysis, and identification of disease-relevant pathogens and their associated antibiotic resistance markers. Fundamentally, OpGen harnesses molecular diagnostics and informatics to actively combat infectious diseases. The company empowers clinicians by providing crucial insights into life-threatening infections, thereby enhancing patient outcomes and significantly slowing the spread of infections caused by multidrug-resistant microorganisms. In a notable collaboration, OpGen is partnered with the New York State Department of Health and ILÚM Health Solutions, LLC, to establish a research program. This initiative focuses on the detection, tracking, and effective management of antimicrobial-resistant infections within healthcare institutions. Established in 2001, OpGen, Inc. maintains its corporate headquarters in Rockville, Maryland.
Fri, 27 Feb 2026
CapForce Inc. (OPGN) rebrands from OpGen and adds 2026 evergreen equity plan - Stock Titan
Fri, 27 Feb 2026
OpGen rebrands as CapForce, moves into digital investment banking - Stock Titan
Thu, 24 Apr 2025
OPGN Stock Price, News & Analysis | Opgen - Stock Titan
Fri, 27 Dec 2024
OpGen faces Nasdaq delisting, to trade OTC - Investing.com
Sat, 07 Sep 2024
Opgen Inc (OPGN) Stock Price and News - The Globe and Mail
Thu, 16 May 2024
OpGen Announced 1-for-10 Reverse Stock Split - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|